PeptiFinder Biotech is committed to empower our clients spearheading groundbreaking innovative medicines to address unmet medical needs and enhancing the quality of life for patients worldwide.

PeptiFinder leverages its proprietary mRNA display libraries and meticulously refined workflow to facilitate the generation of ultra-high diversity (10¹³ ~ 10¹⁵) peptide libraries with exceptional efficiency.

This enables the identification of highly potent and selective linear or macrocyclic peptide candidates, laying solid foundations for the development of a diverse forms of therapeutic molecules including peptides, macrocycles, antibodies, and their derivatives such as peptide-drug conjugate (radioligand therapy), multi-functional peptide conjugates (MPC), antibody-drug conjugates, CarT, peptidomimetics, etc.

Through advanced mRNA display technology, proprietary libraries, and efficient workflows, PeptiFinder is well-positioned to assist our clients in overcoming key bottlenecks in early drug discovery. We are committed to collaborating closely with our clients and partners to advance the development of transformative treatments and diagnostic solutions, ultimately improving patient outcomes on a global scale.